NASDAQ-NMS:PTCT

PTC Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, May 2, 2024
PTC Therapeutics, Therapy, PTC

WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:

Key Points: 
  • WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
    The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
  • It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

Retrieved on: 
Thursday, April 11, 2024
Therapy, PTC Therapeutics, PTC

SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m.
  • To access the call by phone, please click here to register and you will be provided with dial-in details.
  • To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
  • The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .

PTC Therapeutics Provides Key Regulatory Updates

Retrieved on: 
Tuesday, March 19, 2024
PTC Therapeutics, MAA, Ataluren, Patient, PKU, NDA, EMA, Eladocagene exuparvovec, Duchenne muscular dystrophy, Therapy, PTC, FDA, AADC, BLA, Pharmaceutical industry

SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. In addition, based on recent feedback from the FDA, PTC plans to re-submit an NDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC expects to make the NDA resubmission by mid-year.

Key Points: 
  • SOUTH PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.
  • In addition, based on recent feedback from the FDA, PTC plans to re-submit an NDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
  • PTC expects to make the NDA resubmission by mid-year.
  • The data collected to date continue to demonstrate the transformative clinical benefits the gene therapy provides to patients," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics.

PTC Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024
PTC Therapeutics, PTC, Therapy

SOUTH PLAINFIELD, N.J., Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:

Key Points: 
  • SOUTH PLAINFIELD, N.J., Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
    The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation.
  • It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024
PTC Therapeutics, EST, PTC, Therapy

SOUTH PLAINFIELD, N.J., Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.
  • To access the call by phone, please click here to register and you will be provided with dial-in details.
  • To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
  • The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Nikolaus Friedreich, Regulation, Conference, Eladocagene exuparvovec, Economics, PTC, EMA, FDA, MAA, Friedreich's ataxia, Duchenne muscular dystrophy, FA, NDA, Deflazacort, Prescription, HD, Civil service commission, Therapy, Bank statement, PTC Therapeutics, Cardinal, DMD, PKU, European, Duchenne, AADC, Patient, ALS, GAAP, CHMP, BLA, Pharmaceutical industry

SOUTH PLAINFIELD, N.J., Jan. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan Healthcare Conference today, Monday, January 8, at 10:30am EST/7:30am PST. Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2023 accomplishments and highlight potential 2024 value-creating milestones. Preliminary 2023 unaudited financial results and 2024 financial guidance will also be provided. The presentation is being webcast live on the Events and Presentations page of the Investors section of PTC Therapeutics website at www.ptcbio.com.

Key Points: 
  • Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics, will provide an update on 2023 accomplishments and highlight potential 2024 value-creating milestones.
  • The presentation is being webcast live on the Events and Presentations page of the Investors section of PTC Therapeutics website at www.ptcbio.com .
  • PTC announced strategic portfolio prioritizations, which resulted in reductions in both operating expenses and headcount of approximately 25% and 30%, respectively.
  • PTC maintains all economics associated with up to $250 million in the remaining commercial sales milestones associated with Evrysdi global net sales.

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

Retrieved on: 
Tuesday, December 5, 2023
NDA, STRIDE, Food, Therapy, PTC Therapeutics, European Commission, Type, Disease, PTC, Civil service commission, Patient, FDA, CHMP, Committee, File, Ataluren

SOUTH PLAINFIELD, N.J., Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.
  • The re-examination procedure will focus only on the renewal of the existing conditional marketing authorization.
  • "PTC continues to work to secure global registrations that will enable access to Translarna for patients with nmDMD worldwide," said Matthew B. Klein, M.D., Chief Executive Officer of PTC.
  • In the U.S., we look forward to continuing to work collaboratively with FDA on the contents of a potential NDA resubmission."

Thinking about buying stock in Rivian Automotive, Heritage Global, Enphase Energy, PTC Therapeutics, or Hanryu Holdings?

Retrieved on: 
Friday, October 27, 2023
Wall Street, Main Street, Multimedia, Security (finance)

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results 

Retrieved on: 
Monday, October 16, 2023
Therapy, PTC Therapeutics, PTC, Cryptocurrency, Online shopping

SOUTH PLAINFIELD, N.J., Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m.
  • To access the call by phone, please click here to register and you will be provided with dial-in details.
  • To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call.
  • The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .

CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

Retrieved on: 
Friday, September 15, 2023
PTC Therapeutics, Duchenne muscular dystrophy, CHMP-FM, PTC, European Medicines Agency, Committee for Medicinal Products for Human Use, Committee, EMA, DMD, Patient, STRIDE, Therapy, EC, News, Disease, CHMP, Vaccine, Dietary supplement, Ataluren

SOUTH PLAINFIELD, N.J., Sept. 15, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization. PTC plans to submit a request for re-examination per EMA guidelines. Translarna will remain on the market and available to patients with nmDMD until the re-examination process is completed. Based on CHMP procedural guidance, the opinion following the re-examination process would be expected to occur in January 2024, with EC ratification of the opinion within the following 67 days.

Key Points: 
  • The negative opinion also applies to the renewal of the existing conditional authorization.
  • Based on CHMP procedural guidance, the opinion following the re-examination process would be expected to occur in January 2024, with EC ratification of the opinion within the following 67 days.
  • We will be submitting a request for re-examination to the CHMP to reverse this opinion, as we have done previously in the regulatory history of Translarna in Europe."
  • Translarna received conditional marketing authorization in Europe in 2014 based on the results of Study 007, and the conditional authorization was renewed in 2017.